World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
96
Citations
38186
World Ranking
9573
National Ranking
4932

Overview

Richard T. Maziarz is affiliated with Oregon Health & Science University in the United States and has contributed extensively to the field of medicine, with a primary research focus on oncology, hematology, and immunology.

Their recent research output includes publications that span multiple high-impact journals and cover topics such as CAR-T cell therapy, hematopoietic stem cell transplantation, and acute myeloid leukemia. Notable recent papers include:

  • "Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study" (2021, The Lancet Oncology)
  • "Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma" (2021, New England Journal of Medicine)
  • "Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL" (2020, Blood Advances)
  • "Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia" (2020, Bone Marrow Transplantation)
  • "Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial" (2021, Transplantation and Cellular Therapy)

Their frequent co-authors demonstrate collaborative relationships across various research groups and include:

  • Joseph P. McGuirk
  • Stephen J. Schuster
  • Miguel-Angel Perales
  • Gabrielle Meyers
  • Brandon Hayes-Lattin

Richard T. Maziarz's most common publication venues reflect a focus on both clinical and translational hematologic research:

  • Transplantation and Cellular Therapy (58 publications)
  • Blood (42 publications)
  • Cytotherapy (31 publications)
  • Blood Advances (16 publications)
  • Clinical Lymphoma Myeloma & Leukemia (14 publications)

Their work is concentrated in the field of medicine with an emphasis on oncology and hematology. Among the subfields contributing to their research output are:

  • Oncology
  • Hematology
  • Immunology
  • Genetics
  • Public Health, Environmental and Occupational Health

The primary topics addressed in their research include:

  • CAR-T cell therapy research
  • Hematopoietic Stem Cell Transplantation
  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • Lymphoma Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Polyomavirus and related diseases

Best Publications

  • Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Stephen J. Schuster;Michael R. Bishop;Constantine S. Tam;Edmund K. Waller

  • Lenalidomide after stem-cell transplantation for multiple myeloma

    Philip L. McCarthy;Kouros Owzar;Craig C. Hofmeister;David D. Hurd

  • Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients

    Hillard M. Lazarus;Omer N. Koc;Steven M. Devine;Peter Curtin

  • Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors

    Claudio Anasetti;Brent R. Logan;Stephanie J. Lee;Edmund K. Waller

  • Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

    John F. DiPersio;Ivana N. Micallef;Patrick J. Stiff;Brian J. Bolwell

  • Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

    John F. DiPersio;Edward A. Stadtmauer;Auayporn Nademanee;Ivana N.M. Micallef

  • Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

    Philippe Armand;Haesook T. Kim;Brent R. Logan;Zhiwei Wang

  • Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome

    Brian L. McClune;Daniel J. Weisdorf;Tanya L. Pedersen;Gisela Tunes da Silva

  • Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

    Bart L. Scott;Marcelo C. Pasquini;Brent R. Logan;Juan Wu

  • Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial

    Drew J. Winston;Richard T. Maziarz;Pranatharthi H. Chandrasekar;Hillard M. Lazarus

  • Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

    Stephen J. Schuster;Constantine S. Tam;Peter Borchmann;Nina Worel

  • Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation

    John R. Wingard;Shelly L. Carter;Thomas J. Walsh;Joanne Kurtzberg

  • Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure

    Michel Duval;John P. Klein;Wensheng He;Jean Yves Cahn

  • Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

    Koen Van Besien;Fausto R. Loberiza;Ruta Bajorunaite;James O. Armitage

  • Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation

    Mohamed L. Sorror;Rainer F. Storb;Brenda M. Sandmaier;Richard T. Maziarz

  • Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations

    Sergio Giralt;Luciano Costa;Jeffrey Schriber;John DiPersio

  • Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

    Michael B. Maris;Brenda M. Sandmaier;Barry E. Storer;Thomas Chauncey

  • Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma

    Lauri M. Burroughs;Paul V. O'Donnell;Brenda M. Sandmaier;Barry E. Storer

  • Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

    Mohamed L. Sorror;Barry E. Storer;Brenda M. Sandmaier;Michael Maris

  • Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

    Mohamed Sorror;Barry Storer;Barry Storer;Brenda M. Sandmaier;Brenda M. Sandmaier;David G. Maloney;David G. Maloney

Frequent Co-Authors

David G. Maloney
David G. Maloney Fred Hutchinson Cancer Research Center
Brenda M. Sandmaier
Brenda M. Sandmaier Fred Hutchinson Cancer Research Center
Barry E. Storer
Barry E. Storer Fred Hutchinson Cancer Research Center
Hillard M. Lazarus
Hillard M. Lazarus Case Western Reserve University
Rainer Storb
Rainer Storb Fred Hutchinson Cancer Research Center
Michael A. Pulsipher
Michael A. Pulsipher University of Utah
Mary M. Horowitz
Mary M. Horowitz Medical College of Wisconsin
Parameswaran Hari
Parameswaran Hari Medical College of Wisconsin
Vikas Gupta
Vikas Gupta Princess Margaret Cancer Centre
Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Aspiring medical professionals have many alternative and complementary degree paths beyond the traditional MD. As the healthcare field diversifies, options like Healthcare Administration, Nursing Practice, Pharmacy, and Health Information Management are increasingly in demand.

For those interested in leadership roles, understanding the cost of mha degree programs is essential, as these master's degrees can be expensive but offer excellent long-term career prospects. Alternatively, registered nurses looking to advance their practice may consider online doctoral options; those seeking the cheapest dnp programs can gain top clinical credentials while managing their budgets.

For students intrigued by pharmaceuticals, accredited online pharmacy programs offer advanced training and flexibility for working professionals. Meanwhile, tech-savvy individuals can start or pivot their careers quickly with a him associate degree online, focusing on electronic health systems and patient data integrity.

Each of these online pathways provides unique opportunities within healthcare, allowing students to tailor their education to evolving industry needs while considering both cost and career advancement.

Best Scientists Citing Richard T. Maziarz

Trending Scientists